Sanofi-aventis is one of the world’s leading Pharmaceutical companies.
 
Present in more than 100 countries, with around 11,000 scientists, we have around 100,000 employees working to improve health and wellbeing. Our Global headquarters are in Paris, France. 

Sanofi-aventis focuses its activities on 7 major therapeutic areas:

• Cardiovascular
• Thrombosis
• Oncology 
• Central Nervous System
• Metabolic Disorders 
• Internal Medicine
• Vaccines     

The sanofi-aventis portfolio of marketed products includes several medicines that are world leaders in their respective classes, in the areas of thrombosis, cardiovascular disease, sleep disorders, epilepsy, diabetes and cancer. 
 
In Pakistan sanofi-aventis markets Actonel, Amaryl, Clexane, Eloxatin, Epilim, Lantus, Nasacort, Stilnox, Telfast, Taxotere, Tritace among other products.

Sanofi-aventis R&D’s main objective is to provide patients with effective well-tolerated medicines, at the earliest possible time. When it comes to diseases that are difficult to treat, such as Alzheimer’'D5s or depression, oncology or diabetes, we increase our chances of developing groundbreaking treatments that will provide real patient benefit by multiplying and diversifying pharmacological and scientific approaches. This is the reason why clinical trials may be carried out simultaneously on different compounds to treat the same disease and indication.
 
Furthermore, research must take into account the amazing complexity of the human body. Division into therapeutic areas is a way of isolating systems whose functions are sometimes interconnected. Cooperation and exchange between the various teams are crucial in the early stages as a way of identifying processes, which are common to different systems. For this reason, certain compounds may sometimes be under study in programmes involving two different therapeutic areas.

• Cardiovascular disease 
• Thrombosis 
• Cancer 
• Neurodegenerative diseases 
• Diabetes and metabolic disorders 
• Allergies and infectious diseases     

These diseases are crucial public health issues because they are the principal causes of global mortality. It is for that reason that sanofi-aventis has concentrated its research efforts on those subjects for which the Group has developed world-renowned Expertise.